Neutra Corp. (NTRR) intrinsic value & 10-year financials

Neutra Corp. (NTRR) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 164.9% a year to $68.0K, with an average return on invested capital of 96.4%.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$0.00
Revenue (FY2023)
$68.0K
Revenue growth (10-yr CAGR)
164.9%
ROIC (10-yr avg)
96.4%
Free cash flow (FY2023)
—

NTRR 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2023 $68.0K -$561.4K — — -437.8% 29.1%
FY2022 $92.0K -$632.9K — -$445.8K -634.2% 56.5%
FY2021 $9.7K -$538.9K — -$608.9K -4941.3% 52.7%
FY2020 — — — — — —
FY2019 — -$2.4M — — — 259.8%
FY2018 — -$519.0K — — — 339.9%
FY2017 — -$867.9K — — — 1860.1%
FY2016 — -$1.4M — — — -2429.2%
FY2015 — -$1.9M — — — 420.0%
FY2014 — -$1.3M — — — 278.6%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

NEUTRA CORP. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

NEUTRA CORP. has earned high returns on invested capital, averaging 16.2% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.

NEUTRA CORP. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, NEUTRA CORP. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment.

NTRR stock: frequently asked questions

What is NTRR's return on invested capital?

Average ROIC over the last 10 fiscal years was 96.4%, and average return on equity was 187.9%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this NTRR data come from?

From Neutra Corp.'s annual 10-K filings on SEC EDGAR, most recently filed Aug 7, 2024. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar medicinal chemicals & botanical products stocks